| Tumor mutation burden and cancer treatment MJ Fusco, HJ West, CM Walko JAMA oncology 7 (2), 316-316, 2021 | 73 | 2021 |
| Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer MJ Fusco, D Saeed-Vafa, EM Carballido, TA Boyle, M Malafa, KL Blue, ... JCO Precision Oncology 5, 65-74, 2021 | 29 | 2021 |
| Regulatory implications of ctDNA in immuno-oncology for solid tumors PJ Vellanki, S Ghosh, A Pathak, MJ Fusco, EW Bloomquist, S Tang, ... Journal for ImmunoTherapy of Cancer 11 (2), e005344, 2023 | 21 | 2023 |
| Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas MJ Fusco, Y Piña, RJ Macaulay, S Sahebjam, PA Forsyth, E Peguero, ... Cancer Control 28, 10732748211040013, 2021 | 12 | 2021 |
| Evaluation of targeted next-generation sequencing for the management of patients diagnosed with a cancer of unknown primary MJ Fusco, TC Knepper, J Balliu, A Del Cueto, JM Laborde, SM Hooda, ... The Oncologist 27 (1), e9-e17, 2022 | 10 | 2022 |
| Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development ES Duke, M J. Fusco, P DeMoss, A Dilawari, GE Pamuk, J Boehmer, ... Cancer Discovery 12 (12), 2739-2746, 2022 | 6 | 2022 |
| Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma Y Piña, MJ Fusco, RJ Macaulay, CM Walko, E Peguero, BR Evernden, ... Journal of Neurology 267, 783-790, 2020 | 6 | 2020 |
| Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact. M Fusco, RJ Macaulay, PAJ Forsyth, CM Walko Journal of Clinical Oncology 37 (15_suppl), 2058-2058, 2019 | 2 | 2019 |
| FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer MJ Fusco, SJ Casak, SL Mushti, J Cheng, BJ Christmas, MD Thompson, ... Clinical Cancer Research, 2024 | | 2024 |
| Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development JM Donaldson, M Seddiq, MJ Fusco, S Singla, GE Pamuk, RJ Lee-Alonso, ... Cancer Discovery 13 (12), 2515-2524, 2023 | | 2023 |
